CA2095925A1 - Erythrocytes and thrombo-erythrocytes as target specific abents - Google Patents

Erythrocytes and thrombo-erythrocytes as target specific abents

Info

Publication number
CA2095925A1
CA2095925A1 CA002095925A CA2095925A CA2095925A1 CA 2095925 A1 CA2095925 A1 CA 2095925A1 CA 002095925 A CA002095925 A CA 002095925A CA 2095925 A CA2095925 A CA 2095925A CA 2095925 A1 CA2095925 A1 CA 2095925A1
Authority
CA
Canada
Prior art keywords
erythrocyte
thrombo
erythrocytes
molecule
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002095925A
Other languages
English (en)
French (fr)
Inventor
Barry S. Coller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2095925A1 publication Critical patent/CA2095925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002095925A 1990-11-09 1991-11-12 Erythrocytes and thrombo-erythrocytes as target specific abents Abandoned CA2095925A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61116490A 1990-11-09 1990-11-09
US611,164 1990-11-09

Publications (1)

Publication Number Publication Date
CA2095925A1 true CA2095925A1 (en) 1992-05-10

Family

ID=24447889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002095925A Abandoned CA2095925A1 (en) 1990-11-09 1991-11-12 Erythrocytes and thrombo-erythrocytes as target specific abents

Country Status (7)

Country Link
EP (1) EP0558645A4 (ko)
JP (1) JPH06504535A (ko)
KR (1) KR930702341A (ko)
AU (1) AU651643B2 (ko)
CA (1) CA2095925A1 (ko)
FI (1) FI932114A (ko)
WO (1) WO1992008804A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
GB9705787D0 (en) 1997-03-20 1997-05-07 Thrombosis Res Inst Modified dendroaspins
WO1999034680A1 (en) * 1998-01-06 1999-07-15 Trustees Of Boston University Decorated red blood cells
DE10038900A1 (de) * 2000-08-09 2002-03-07 Haemosys Gmbh Einfache Methode zum drug monitoring von GPIIb/IIIa-Rezeptor-Antagonisten
US7195919B2 (en) * 2003-12-19 2007-03-27 Beckman Coulter, Inc. Hematology controls for reticulocytes and nucleated red blood cells
DE102004054536A1 (de) * 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
EP1984391A4 (en) * 2006-01-19 2009-08-12 Eyegene Inc PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM
EP1849482A1 (en) * 2006-04-25 2007-10-31 Capsulution Nanoscience AG Multimodally altered cells as a form for administering active substances and as diagnostic particles
KR100824396B1 (ko) 2006-10-10 2008-04-22 (주)케어젠 상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도
CN101625267B (zh) * 2008-07-11 2011-07-20 财团法人工业技术研究院 热侦测系统及其侦测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4988621A (en) * 1985-05-24 1991-01-29 La Jolla Cancer Research Foundation Peptides in cell detachment and aggregation
JPS62190129A (ja) * 1986-02-18 1987-08-20 Green Cross Corp:The 制癌剤含有マイクロキヤリアの製造方法
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles

Also Published As

Publication number Publication date
EP0558645A1 (en) 1993-09-08
KR930702341A (ko) 1993-09-08
AU9058891A (en) 1992-06-11
FI932114A0 (fi) 1993-05-10
FI932114A (fi) 1993-07-01
AU651643B2 (en) 1994-07-28
JPH06504535A (ja) 1994-05-26
WO1992008804A1 (en) 1992-05-29
EP0558645A4 (en) 1994-07-06

Similar Documents

Publication Publication Date Title
US5328840A (en) Method for preparing targeted carrier erythrocytes
Vogt et al. Interaction of cationized antigen with rat glomerular basement membrane: In situ immune complex formation
Coller et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions.
JP3926839B2 (ja) 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5110730A (en) Human tissue factor related DNA segments
CA2000048A1 (en) Peptides and antibodies that inhibit integrin-ligand bindin g
AU651643B2 (en) Erythrocytes and thrombo-erythrocytes as target specific agents
JP2846470B2 (ja) Ｈｌａペプチドによるリンパ球活性の調節
CA2082272A1 (en) Molecular recognition units
JPH05501400A (ja) アポリポタンパクｅのポリペプチド類似体、診断系および該類似体の使用法
US5620956A (en) Methods of using CD8 binding domain peptides
CA1339185C (en) Lymphocyte inhibition by hla peptides
CA2541005C (en) Fibrinogen targetting microparticles for promoting haemostasis
AU676483B2 (en) Polypeptides, derived from endonexin 2, having hepatitis B virus receptor activity and their use in diagnostic and pharmaceutical compositions
JPH10511954A (ja) 抗炎症ｃｄ１４ペプチド
Wholey et al. Synthetic liposomal mimics of biological viruses for the study of immune responses to infection and vaccination
JP2001511762A (ja) 選択性スロンビン抑制剤としてのブラジキニン同族体
Fu et al. Immunocytochemical localization of M2 muscarinic receptors in rat ventricles with anti-peptide antibodies.
EP0333517A2 (en) Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
WO1993016712A1 (en) MUTANT GPIbα FRAGMENTS AND RECOMBINANT EXPRESSION THEREOF
WO1996011700A1 (en) Reduction of mammalian neoplasms with phospholipase a2 activatiing substances
JPH08511941A (ja) ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用
WO1998017242A1 (en) Unique peptides for targeting fibronectin-enriched surfaces and a method for their delivery in the treatment of metastatic cancer
CA2324864A1 (en) Immune response modulator alpha-2 macroglobulin complex
CA2392387A1 (en) Polypeptides and methods for thymic vaccination

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19960512